Annexon Reiterates ARCHER II Design and Timeline in Geographic Atrophy Discussion

What happened

Annexon held a discussion call regarding its Phase III ARCHER II trial of vonaprument in geographic atrophy, with management providing an update on the trial's status. The trial, which previously completed enrollment of 659 patients in July 2025, is designed to evaluate whether vonaprument can prevent a ≥15-letter loss in best-corrected visual acuity versus sham. Management reiterated that topline results are expected in the second half of 2026, consistent with prior guidance. No new efficacy or safety data were disclosed during the discussion, limiting the information value of the event. The company's lead program, tanruprubart for Guillain-Barré syndrome, remains the primary value driver, while ARCHER II serves as a secondary catalyst that could diversify the pipeline.

Implication

Given the absence of new data, the event likely has minimal impact on near-term stock performance. However, continued execution on ARCHER II is important, as a positive outcome would expand the company's addressable market and reduce reliance on GBS. Conversely, a failure could shift focus entirely to GBS and increase risk. Monitoring trial integrity and patient enrollment adherence is key.

Thesis delta

The thesis remains unchanged: Annexon's primary value lies in tanruprubart for GBS, with vonaprument for GA as a secondary opportunity. The ARCHER II discussion provides no new information that would alter our view on the probability of success or timing. We continue to see the risk-reward as favorable at current levels, contingent on regulatory milestones.